Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University

Silvia Würstle; Alina Lee; Kaitlyn E. Kortright; Franziska Winzig; William An; Gail L. Stanley; Govindarajan Rajagopalan; Zach Harris; Ying Sun; Buqu Hu; Michael Blazanin; Maryam Hajfathalian; Paul L. Bollyky; Paul E. Turner; Jonathan L. Koff; Benjamin K. Chan

doi:10.1038/s41598-024-52192-3

Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University

Silvia Würstle, Alina Lee, Kaitlyn E. Kortright, Franziska Winzig, William An, Gail L. Stanley, Govindarajan Rajagopalan, Zach Harris, Ying Sun, Buqu Hu, Michael Blazanin, Maryam Hajfathalian, Paul L. Bollyky, Paul E. Turner, Jonathan L. Koff, Benjamin K. Chan

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Bacteriophage therapy is one potential strategy to treat antimicrobial resistant or persistent bacterial infections, and the year 2021 marked the centennial of Felix d’Hérelle’s first publication on the clinical applications of phages. At the Center for Phage Biology & Therapy at Yale University, a preparatory modular approach has been established to offer safe and potent phages for single-patient investigational new drug applications while recognizing the time constraints imposed by infection(s). This study provides a practical walkthrough of the pipeline with an Autographiviridae phage targeting Pseudomonas aeruginosa (phage vB_PaeA_SB, abbreviated to ΦSB). Notably, a thorough phage characterization and the evolutionary selection pressure exerted on bacteria by phages, analogous to antibiotics, are incorporated into the pipeline.

Original language	English (US)
Article number	2657
Journal	Scientific reports
Volume	14
Issue number	1
DOIs	https://doi.org/10.1038/s41598-024-52192-3
State	Published - Dec 2024
Externally published	Yes

All Science Journal Classification (ASJC) codes

General

Access to Document

10.1038/s41598-024-52192-3

Cite this

Würstle, S., Lee, A., Kortright, K. E., Winzig, F., An, W., Stanley, G. L., Rajagopalan, G., Harris, Z., Sun, Y., Hu, B., Blazanin, M., Hajfathalian, M., Bollyky, P. L., Turner, P. E., Koff, J. L., & Chan, B. K. (2024). Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University. Scientific reports, 14(1), Article 2657. https://doi.org/10.1038/s41598-024-52192-3

@article{cfe29f9f57fc44ecafa187c98ff0bdbd,

title = "Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University",

abstract = "Bacteriophage therapy is one potential strategy to treat antimicrobial resistant or persistent bacterial infections, and the year 2021 marked the centennial of Felix d{\textquoteright}H{\'e}relle{\textquoteright}s first publication on the clinical applications of phages. At the Center for Phage Biology & Therapy at Yale University, a preparatory modular approach has been established to offer safe and potent phages for single-patient investigational new drug applications while recognizing the time constraints imposed by infection(s). This study provides a practical walkthrough of the pipeline with an Autographiviridae phage targeting Pseudomonas aeruginosa (phage vB_PaeA_SB, abbreviated to ΦSB). Notably, a thorough phage characterization and the evolutionary selection pressure exerted on bacteria by phages, analogous to antibiotics, are incorporated into the pipeline.",

author = "Silvia W{\"u}rstle and Alina Lee and Kortright, {Kaitlyn E.} and Franziska Winzig and William An and Stanley, {Gail L.} and Govindarajan Rajagopalan and Zach Harris and Ying Sun and Buqu Hu and Michael Blazanin and Maryam Hajfathalian and Bollyky, {Paul L.} and Turner, {Paul E.} and Koff, {Jonathan L.} and Chan, {Benjamin K.}",

note = "Publisher Copyright: {\textcopyright} 2024, The Author(s).",

year = "2024",

month = dec,

doi = "10.1038/s41598-024-52192-3",

language = "English (US)",

volume = "14",

journal = "Scientific reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

Würstle, S, Lee, A, Kortright, KE, Winzig, F, An, W, Stanley, GL, Rajagopalan, G, Harris, Z, Sun, Y, Hu, B, Blazanin, M, Hajfathalian, M, Bollyky, PL, Turner, PE, Koff, JL & Chan, BK 2024, 'Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University', Scientific reports, vol. 14, no. 1, 2657. https://doi.org/10.1038/s41598-024-52192-3

TY - JOUR

T1 - Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University

AU - Würstle, Silvia

AU - Lee, Alina

AU - Kortright, Kaitlyn E.

AU - Winzig, Franziska

AU - An, William

AU - Stanley, Gail L.

AU - Rajagopalan, Govindarajan

AU - Harris, Zach

AU - Sun, Ying

AU - Hu, Buqu

AU - Blazanin, Michael

AU - Hajfathalian, Maryam

AU - Bollyky, Paul L.

AU - Turner, Paul E.

AU - Koff, Jonathan L.

AU - Chan, Benjamin K.

PY - 2024/12

Y1 - 2024/12

N2 - Bacteriophage therapy is one potential strategy to treat antimicrobial resistant or persistent bacterial infections, and the year 2021 marked the centennial of Felix d’Hérelle’s first publication on the clinical applications of phages. At the Center for Phage Biology & Therapy at Yale University, a preparatory modular approach has been established to offer safe and potent phages for single-patient investigational new drug applications while recognizing the time constraints imposed by infection(s). This study provides a practical walkthrough of the pipeline with an Autographiviridae phage targeting Pseudomonas aeruginosa (phage vB_PaeA_SB, abbreviated to ΦSB). Notably, a thorough phage characterization and the evolutionary selection pressure exerted on bacteria by phages, analogous to antibiotics, are incorporated into the pipeline.

AB - Bacteriophage therapy is one potential strategy to treat antimicrobial resistant or persistent bacterial infections, and the year 2021 marked the centennial of Felix d’Hérelle’s first publication on the clinical applications of phages. At the Center for Phage Biology & Therapy at Yale University, a preparatory modular approach has been established to offer safe and potent phages for single-patient investigational new drug applications while recognizing the time constraints imposed by infection(s). This study provides a practical walkthrough of the pipeline with an Autographiviridae phage targeting Pseudomonas aeruginosa (phage vB_PaeA_SB, abbreviated to ΦSB). Notably, a thorough phage characterization and the evolutionary selection pressure exerted on bacteria by phages, analogous to antibiotics, are incorporated into the pipeline.

UR - http://www.scopus.com/inward/record.url?scp=85183804317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85183804317&partnerID=8YFLogxK

U2 - 10.1038/s41598-024-52192-3

DO - 10.1038/s41598-024-52192-3

M3 - Article

C2 - 38302552

AN - SCOPUS:85183804317

SN - 2045-2322

VL - 14

JO - Scientific reports

JF - Scientific reports

IS - 1

M1 - 2657

ER -

Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this